The ‘long tail’ problem: injected-PrEP trial will be extended due to persistence of drug in companion study
Ibalizumab monoclonal antibody looks promising for people with drug-resistant HIV
New long-acting fusion inhibitor albuvirtide plus boosted protease inibitor matches standard triple-drug therapy
Long-acting injectable drugs work well for HIV maintenance therapy
Long-acting oral antiretroviral MK-8591 could represent 'paradigm shift' in HIV treatment and prophylaxis
Long-acting injectable cabotegravir + rilpivirine works well as HIV maintenance therapy
Cabotegravir and rilpivirine effective for HIV maintenance therapy at 96 weeks
Injectable cabotegravir makes progress towards human efficacy studies: doubts about injectable rilpivirine
Novel two-drug maintenance combination works at least as well as triple therapy: stage set for long-lasting injectable formulation
